Waldron LP bought a new position in shares of GlaxoSmithKline PLC (NYSE:GSK) in the third quarter, according to the company in its most recent filing with the SEC. The firm bought 5,000 shares of the pharmaceutical company’s stock, valued at approximately $203,000.

Several other institutional investors have also recently made changes to their positions in the stock. Keystone Financial Planning Inc. increased its position in shares of GlaxoSmithKline PLC by 1.7% during the 3rd quarter. Keystone Financial Planning Inc. now owns 133,216 shares of the pharmaceutical company’s stock worth $5,409,000 after purchasing an additional 2,210 shares in the last quarter. Spectrum Management Group Inc. acquired a new stake in shares of GlaxoSmithKline PLC during the 3rd quarter worth about $505,000. Ameriprise Financial Inc. increased its position in shares of GlaxoSmithKline PLC by 7.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 1,855,142 shares of the pharmaceutical company’s stock worth $75,028,000 after purchasing an additional 122,634 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of GlaxoSmithKline PLC during the 3rd quarter worth about $1,209,000. Finally, Advisors Asset Management Inc. increased its position in shares of GlaxoSmithKline PLC by 8.5% during the 3rd quarter. Advisors Asset Management Inc. now owns 171,442 shares of the pharmaceutical company’s stock worth $6,961,000 after purchasing an additional 13,447 shares in the last quarter. Institutional investors and hedge funds own 9.32% of the company’s stock.

A number of equities research analysts recently issued reports on GSK shares. TheStreet upgraded shares of GlaxoSmithKline PLC from a “c+” rating to a “b” rating in a research report on Wednesday, October 25th. Zacks Investment Research upgraded shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a research report on Wednesday, October 18th. Argus reiterated a “buy” rating and set a $50.00 target price on shares of GlaxoSmithKline PLC in a research report on Thursday, August 31st. Investec cut shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research report on Monday, November 6th. Finally, J P Morgan Chase & Co reiterated a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Monday, July 24th. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating and five have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $44.33.

Shares of GlaxoSmithKline PLC (NYSE:GSK) traded down $0.13 during trading hours on Friday, hitting $35.06. 2,585,265 shares of the stock traded hands, compared to its average volume of 6,982,297. GlaxoSmithKline PLC has a 12 month low of $34.72 and a 12 month high of $44.53. The company has a debt-to-equity ratio of 2.96, a quick ratio of 0.44 and a current ratio of 0.64. The firm has a market cap of $86,224.50, a PE ratio of 12.43, a price-to-earnings-growth ratio of 1.94 and a beta of 1.00.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, January 11th. Stockholders of record on Friday, November 10th will be given a dividend of $0.5037 per share. This is a boost from GlaxoSmithKline PLC’s previous quarterly dividend of $0.49. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $2.01 annualized dividend and a dividend yield of 5.75%. GlaxoSmithKline PLC’s payout ratio is currently 163.12%.

In other GlaxoSmithKline PLC news, major shareholder Plc Glaxosmithkline purchased 428,571 shares of the stock in a transaction dated Monday, November 6th. The stock was bought at an average price of $14.00 per share, for a total transaction of $5,999,994.00. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 10.00% of the stock is owned by insiders.

COPYRIGHT VIOLATION WARNING: This article was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international trademark and copyright law. The legal version of this article can be read at https://www.thecerbatgem.com/2017/11/19/5000-shares-in-glaxosmithkline-plc-gsk-purchased-by-waldron-lp.html.

About GlaxoSmithKline PLC

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Stock Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related stocks with our FREE daily email newsletter.